¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÉÀåÇÐȸ (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2021-04-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÉÀåÇÐȸ (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2021-04-16
±³À°ÀÏÀÚ : 2021-04-16
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 8 ½Ã°£ 35ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í ±³¼ö ¹× °³¿øÀÇ: 20000¿ø/ÀüÀÓÀÇ, Àü°øÀÇ, ±âŸ: 10000¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ09:30~09:50 Optimal Choice and Duration of Antiplatelet Therapy in AMI  Á¤¿µÈÆ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ09:50~10:10 Timing of PCI for Nonculprit Lesion in STEMI  ÃÖö¿õ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ10:10~10:30 Intracoronary Imaging-Guided PCI Can Improve Outcomes in AMI?  À̼ºÀ±(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ10:30~10:50 Lipid Lowering Therapy in AMI: From Guidelines to Implementation  Á¶°æÈÆ(Àü³²ÀÇ´ë) 
Åä·Ð 04¿ù 16ÀÏ ¿Â¶óÀΠ10:50~11:00 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ04¿ù 16ÀÏ  11:00~11:10 Break  () 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ11:10~11:20 Mechanisms and Risk Factors of AF  ¹ÚÁø±Ô(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ11:20~11:30 AF screening: present and future  ÀÌÁ¤¸í(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ11:30~11:40 Medical Rhythm Control for AF  ¹ÚÇü¿í(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ11:40~11:50 Does Catheter Ablation of AF Improve Survival?  ¾çÇʼº(Â÷ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ11:50~12:00 Catheter Ablation of AF: Current Strategy  ¹ÚÇü¼·(°è¸íÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ12:00~12:10 Update in Cryoablation of AF as An Initial Treatment  ½ÉÀç¹Î(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ12:10~12:20 Treatment for Patients with AF and HF  ¾È¹Î¼ö(¿¬¼¼¿øÁÖÀÇ´ë) 
Åä·Ð 04¿ù 16ÀÏ ¿Â¶óÀΠ12:20~12:40 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ04¿ù 16ÀÏ  12:40~12:45 Break  () 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ12:45~13:05 How to Manage &quotAge  Steven Deitelzweig(Ochsner. US) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ13:05~13:25 What Are the Characteristics of AF in Asian Patients? Addressing Issues and Challenges  ±èÅÂÈÆ(¿¬¼¼ÀÇ´ë) 
È޽Ġ04¿ù 16ÀÏ  13:25~13:40 Break  () 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ12:45~14:30 Abstract/Case Session  ´Ù°­»ç(´Ù¼Ò¼Ó) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ14:30~14:45 Hypertension and AF: Pathophysiologic Considerations  Á¶¿µÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ14:45~15:00 Blood Pressure Variability and New On AF  ±ÇâÈñ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ15:00~15:15 Hypertension and AF: Preventive and Therapeutic Implications  ÁøÀº¼±(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ15:15~15:30 Hypertension and AF: Epidemiology in Korea  À̼ҷÉ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ15:30~15:45 Hypertension and AF: Special Considerations in the Elderly  ÃÖÁ¾ÀÏ(°í·ÁÀÇ´ë) 
Åä·Ð 04¿ù 16ÀÏ ¿Â¶óÀΠ15:45~16:00 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
±³À°½Ã°£ 04¿ù 16ÀÏ  16:00~16:10 Break  () 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ16:10~16:25 How to Assess Complex Congenital Heart Disease: Transthoracic Echocardiography  ±è¿©Çâ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ16:25~16:40 Critical Moment with Tansesophageal Echocardiography  À̽¾Æ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ16:40~16:55 Cardiac CT Imaging - Add-on Modality in ACHD Management  °íÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ16:55~17:10 Right Ventricular Function and More - Cardiac MRI in ACHD  ±è¿µÁø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 16ÀÏ ¿Â¶óÀΠ17:10~17:25 Case Based Approach Using Multimodliaty Imaging in ACHD  ¹ÚÁغó(¼­¿ïÀÇ´ë) 
Åä·Ð 04¿ù 16ÀÏ ¿Â¶óÀΠ17:25~17:40 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÉÀåÇÐȸ (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2021-04-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021 ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ Á¦65Â÷ Ãá°èÇмú´ëȸ : 2021-04-16
´ÙÀ½±Û 2021³â ´ëÇѱٰñ°Ý¿µ»óÀÇÇÐȸ ¿Â¶óÀÎ Á¤±âÇмú´ëȸ : 2021-04-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 11 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 17 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 116 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 25 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 102 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 17 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 11 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 9 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 33 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 7 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 13 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 4 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 11 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 12 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 14 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷